Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEX-22A prolonged-release liraglutide in type 2 diabetes
NCT06439056Phase 1Completed
- Sponsor
- Nanexa AB
- Start
- May 2024
- Primary completion
- Jul 2025
- Modality
- Device-based Delivery
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NEX-22 in type 2 diabetes mellitus (T2DM), sponsored by Nanexa AB. Primary endpoints: Area Under the Curve at 36 days, Maximum Plasma Concentration at 36 days and 4 more. Started May 2024; status: completed.
02
Drugs
NEX-22
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06439056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06439056.